Showing 1 to 4 of 4 results
Tax Court Ruling Boosts US Economic Growth Potential
A US Tax Court ruling sided with AbbVie, allowing a $1.6 billion breakup fee to be treated as a business expense, preventing a $572 million tax increase and potentially boosting M&A activity and economic growth.
Tax Court Ruling Boosts US Economic Growth Potential
A US Tax Court ruling sided with AbbVie, allowing a $1.6 billion breakup fee to be treated as a business expense, preventing a $572 million tax increase and potentially boosting M&A activity and economic growth.
Progress
48% Bias Score
Dutch Court to Rule on AbbVie's Humira Pricing Lawsuit
A Dutch court will rule on a lawsuit against AbbVie for allegedly making €1 billion in excessive profits from its rheumatoid arthritis drug Humira (adalimumab) between 2004 and 2018; the foundation Farma ter Verantwoording claims this money could have improved the health of 14,000 people.
Dutch Court to Rule on AbbVie's Humira Pricing Lawsuit
A Dutch court will rule on a lawsuit against AbbVie for allegedly making €1 billion in excessive profits from its rheumatoid arthritis drug Humira (adalimumab) between 2004 and 2018; the foundation Farma ter Verantwoording claims this money could have improved the health of 14,000 people.
Progress
52% Bias Score
Lawsuit Challenges AbbVie's Humira Pricing, Highlighting Drug Cost Debate
A Dutch foundation is suing AbbVie for excessive profits from Humira, arguing its high price displaced other healthcare needs; AbbVie counters that high prices are needed to cover development costs, and the patent expiry in 2018 caused prices to plummet by nearly 90% by 2023.
Lawsuit Challenges AbbVie's Humira Pricing, Highlighting Drug Cost Debate
A Dutch foundation is suing AbbVie for excessive profits from Humira, arguing its high price displaced other healthcare needs; AbbVie counters that high prices are needed to cover development costs, and the patent expiry in 2018 caused prices to plummet by nearly 90% by 2023.
Progress
60% Bias Score
AbbVie Stock Surges 10% on Emrelis Approval and Immunology Growth
AbbVie's stock price surged 10% in six months due to FDA approval of Emrelis for lung cancer and exceptional growth (Skyrizi +71%, Rinvoq +57%) in its immunology portfolio during Q1 2025, despite high valuation and concerns about drug price controls.
AbbVie Stock Surges 10% on Emrelis Approval and Immunology Growth
AbbVie's stock price surged 10% in six months due to FDA approval of Emrelis for lung cancer and exceptional growth (Skyrizi +71%, Rinvoq +57%) in its immunology portfolio during Q1 2025, despite high valuation and concerns about drug price controls.
Progress
40% Bias Score
Showing 1 to 4 of 4 results